Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

about

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis

P2860

Q55417294-69BD9C17-78E6-474A-8191-1B50A85185B1 Q58803309-0F45E3AC-3209-45C7-A99E-DF84B46760A5

P2860

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

Item

http://www.wikidata.org/entity/Q38371450

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

@en

type

Item

label

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

@en

prefLabel

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

@en

P1476

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

@en

P2093

Carter Thorne

http://www.w3.org/2001/XMLSchema#string

George Karpouzas

http://www.w3.org/2001/XMLSchema#string

Kaiyin Fei

http://www.w3.org/2001/XMLSchema#string

Paul P Tak

http://www.w3.org/2001/XMLSchema#string

Ravi Rao

http://www.w3.org/2001/XMLSchema#string

Shihong Sheng

http://www.w3.org/2001/XMLSchema#string

Weichun Xu

http://www.w3.org/2001/XMLSchema#string

P2860

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

P304

2001-2008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2017-211328

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tsutomu Takeuchi

Benjamin Hsu

P577

2017-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28855173

http://www.w3.org/2001/XMLSchema#string

P932

5705845

http://www.w3.org/2001/XMLSchema#string

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

about

P2860

P2860

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932